CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $251.02M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.21M
Average 0.10M
Returns on capital
CAMP4 Therapeutics Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-168.5%
avg -22.6%
ROIC
-50.8%
avg -24.8%
ROA
-68.2%
avg -26.0%
Analysis
ROIC is currently the strongest return metric at -50.8% versus its period average of -24.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joshua Mandel-Brehm | Chief Executive Officer, President & Director | USD 896.25K | 43 | — | — |
Kelly Gold | Chief Financial Officer | USD 734.69K | 49 | 10.00K | 0.05% |
Yuri Maricich | Chief Medical Officer | USD 702K | 45 | 12.61K | 0.06% |
Richard A. Young | Founder & Independent Director | USD 146.56K | 72 | 186.39K | 0.88% |
Daniel Tardiff | Chief Scientific Officer | — | 46 | 0 | <0.01% |
Leonard I. Zon | Founder & Chairman of Scientific Advisory Board | — | — | — | — |
Caleb Moore | Chief Business Operations Officer | — | — | — | — |
Alla Sigova | Senior Vice President of Platform | — | — | — | — |
Michelle Gates | Senior Vice President & Chief People Officer | — | — | — | — |
Satya Kuchimanchi | Senior Vice President of Technical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 31, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$99,369.11
Sells
6
$2.50M
Net Transaction Value
−$2.40M
Net selling
Most Active
Schwab Andrew J.
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 31, 26Aug 31, 2026 | Gold Kelly Indirect | Buy | $39.6K$39,600.00 |
| Aug 27, 26Aug 27, 2026 | Schwab Andrew J. Indirect | Sell | $1.6M$1,616,000.00 |
| Aug 24, 26Aug 24, 2026 | Schwab Andrew J. Indirect | Sell | $45$45.00 |
| Aug 21, 26Aug 21, 2026 | Schwab Andrew J. Indirect | Sell | $144.1K$144,081.00 |
| Aug 20, 26Aug 20, 2026 | Schwab Andrew J. Indirect | Sell | $520.7K$520,738.00 |
| Aug 19, 26Aug 19, 2026 | Tardiff Daniel Direct | Sell | $8.3K$8,272.88 |
| Aug 19, 26Aug 19, 2026 | Schwab Andrew J. Indirect | Sell | $214.9K$214,899.72 |
| Aug 3, 26Aug 3, 2026 | 5AM Partners VI, LLC Indirect | Buy | $318$317.96 |
| Aug 3, 26Aug 3, 2026 | Young Richard A Direct | Buy | $27K$27,023.70 |
| Aug 3, 26Aug 3, 2026 | Maricich Yuri Direct | Buy | $10.8K$10,809.15 |
1–10 of 12
Summary
Insiders reported 6 buys worth $99,369.11 and 6 sells worth $2.50M over the last 12 months. That adds up to net selling of $2.40M. Schwab Andrew J. was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +35.4% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +35.4% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does CAMP4 Therapeutics Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CAMP's management, answered from reported figures.
Who manages CAMP?
CAMP4 Therapeutics Corporation (CAMP) lists 10 active executives. The top listed executive is Daniel Tardiff, Chief Scientific Officer.
Are CAMP insiders buying or selling?
Recent insider activity shows net buying of $95.67M.
Continue the stock analysis
Jump to another research area for this company.